新生内膜增生
再狭窄
兴奋剂
脐静脉
肝X受体
血管平滑肌
药理学
癌症研究
受体
医学
化学
体外
内分泌学
内科学
生物化学
核受体
支架
平滑肌
基因
转录因子
作者
Jian Li,Fan Jia,Zhebin Chen,Jim J. Lin,Qingyu Lv,Yue Huang,Qiao Jin,Youxiang Wang,Guosheng Fu,Jian Ji
出处
期刊:Biomaterials Science
[The Royal Society of Chemistry]
日期:2022-01-01
卷期号:10 (22): 6354-6364
摘要
Restenosis induced by neointimal hyperplasia is one of the key reasons limiting the long-term success of cardiovascular interventional therapy. However, it remains a serious challenge to completely overcome restenosis because of the dilemma of simultaneously activating human umbilical vein endothelial cells (HUVECs) and inhibiting human aortic smooth muscle cells (HASMCs). Herein, we developed a targeted nanomedicine encapsulating the liver X receptor (LXR) agonist, T0901317, for differentially regulating the behaviors of HUVECs and HASMCs. The stimulatory effect on HUVEC proliferation/migration and the inhibitory effect on HASMC proliferation/migration were confirmed in vitro, respectively. In the co-culture system, the competitiveness of HUVECs over HASMCs was notably improved after being treated with T0901317-loaded liposomes. Compared to free T0901317 and non-targeted liposomes, the type IV collagen (Col-IV) targeted liposomes could accumulate in the vascular injured area more effectively and inhibit neointimal hyperplasia in a balloon-induced rat carotid artery injury model. Therefore, targeted delivery of LXR agonist might be a very promising therapeutic strategy for anti-restenosis therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI